Company Overview: Actinium Pharmaceuticals Inc

Industry News

24 May

Actinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Actimab-A

– Orphan designation provides increased communication and guidance from regulators and 10-year market exclusivity upon marketing authorization – Actinium’s two leading drug candidates, Iomab-B and Actimab-A, now have orphan designation in both the U.S. and EU NEW YORK, May 24, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium”...

Read more

17 May

Actinium Pharmaceuticals Announces Appointment of Hematology Expert Dr. Richard Stone of the Dana-Farber Cancer Institute to its Scientific Advisory Board

NEW YORK, May 17, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Dr. Richard Stone, Chief of Staff and Program Director, Acute Leukemia at the Dana-Farber Cancer...

Read more

18 Apr

Actinium Pharmaceuticals Announces Sponsorship of the Acute Leukemia Forum 2017

NEW YORK, April 18, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Actinium is a sponsor of the Acute Leukemia Forum 2017 being held in San Francisco,...

Read more

28 Mar

Actinium Pharmaceuticals Appoints Pharmaceutical Industry Executive Ajit S. Shetty, Ph.D., to the Company’s Board of Directors

NEW YORK, March 28, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Dr. Ajit Shetty has been appointed to the Company’s Board of Directors. Dr. Shetty is...

Read more

21 Mar

Actinium Announces Receipt of Positive Scientific Advice from the European Medicines Agency for Iomab-B

NEW YORK, March 21, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has received positive Scientific Advice from the Committee for Medicinal Products for Human...

Read more

17 Mar

Actinium Pharmaceuticals to Sponsor 4th Annual Summit on Hematologic Malignancies

NEW YORK, March 16, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc.  (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that the Company is a sponsor of Oncology Meeting Innovations’ 4thAnnual Summit on Hematologic Malignancies, which is...

Read more

7 Mar

Actinium Pharmaceuticals to Present at 29th Annual ROTH Conference

NEW YORK, March 07, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc.  (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that Sandesh Seth, Actinium’s Executive Chairman, will be presenting at 29th Annual ROTH Conference being held March...

Read more

28 Feb

Actinium Announces Expansion of Intellectual Property Portfolio with Notice of Allowance for U.S. Patent Related to Actimab-A, Actimab-M and the Company’s Technology Platform

NEW YORK, Feb. 28, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company received a notice of allowance from the United States Patent and Trademark Office...

Read more

21 Feb

Actinium Pharmaceuticals Announces Hiring of Steven Price to Position of Vice President, Clinical and Commercial Strategy

NEW YORK, Feb. 21, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc.  (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that Steven Price has been appointed to the newly created position of Vice President, Clinical and Commercial...

Read more

Page 1 of 912345...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address